COVID-19 vaccination, dengue hepatitis, and recurrent unilateral anterior uveitis
A 36-year-old Asian Indian male presented with redness and pain in his right eye of 1 week duration. He was diagnosed to have right acute anterior uveitis and had a history of being admitted at a local hospital for dengue hepatitis a month earlier. He had been on adalimumab 40 mg three weekly once and oral methotrexate 20 mg/week for human leucocyte antigen (HLA) B27 spondyloarthropathy and recurrent anterior uveitis. Our patient had re-activation of his anterior chamber inflammation on three distinct occasions: first, 3 weeks following recovery from coronavirus disease 2019 (COVID-19), the second after the second dose of COVID-19 vaccination, and the third after recovery from dengue fever-associated hepatitis. We propose molecular mimicry and bystander activation as the postulated mechanisms for the re-activation of his anterior uveitis. In conclusion, patients with auto-immune diseases can have recurrent ocular inflammation following COVID-19 or its vaccination or dengue fever as seen in our patient. The anterior uveitis is usually mild and responds to topical steroids. Additional immuno-suppression may not be needed. Mild ocular inflammation following vaccination should not deter individuals from getting COVID-19 vaccination.
| Errataetall: |
CommentOn: J Ophthalmic Inflamm Infect. 2022 Jan 4;12(1):4. - PMID 34982290 |
|---|---|
| Medienart: |
E-Artikel |
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:71 |
|---|---|
| Enthalten in: |
Indian journal of ophthalmology - 71(2023), 5 vom: 01. Mai, Seite 2269-2272 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Sanjay, Srinivasan [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Adalimumab |
|---|
| Anmerkungen: |
Date Completed 22.05.2023 Date Revised 03.08.2023 published: Print CommentOn: J Ophthalmic Inflamm Infect. 2022 Jan 4;12(1):4. - PMID 34982290 Citation Status MEDLINE |
|---|
| doi: |
10.4103/ijo.IJO_2064_22 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM357055039 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM357055039 | ||
| 003 | DE-627 | ||
| 005 | 20231226071752.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.4103/ijo.IJO_2064_22 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1190.xml |
| 035 | |a (DE-627)NLM357055039 | ||
| 035 | |a (NLM)37202968 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Sanjay, Srinivasan |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a COVID-19 vaccination, dengue hepatitis, and recurrent unilateral anterior uveitis |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 22.05.2023 | ||
| 500 | |a Date Revised 03.08.2023 | ||
| 500 | |a published: Print | ||
| 500 | |a CommentOn: J Ophthalmic Inflamm Infect. 2022 Jan 4;12(1):4. - PMID 34982290 | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a A 36-year-old Asian Indian male presented with redness and pain in his right eye of 1 week duration. He was diagnosed to have right acute anterior uveitis and had a history of being admitted at a local hospital for dengue hepatitis a month earlier. He had been on adalimumab 40 mg three weekly once and oral methotrexate 20 mg/week for human leucocyte antigen (HLA) B27 spondyloarthropathy and recurrent anterior uveitis. Our patient had re-activation of his anterior chamber inflammation on three distinct occasions: first, 3 weeks following recovery from coronavirus disease 2019 (COVID-19), the second after the second dose of COVID-19 vaccination, and the third after recovery from dengue fever-associated hepatitis. We propose molecular mimicry and bystander activation as the postulated mechanisms for the re-activation of his anterior uveitis. In conclusion, patients with auto-immune diseases can have recurrent ocular inflammation following COVID-19 or its vaccination or dengue fever as seen in our patient. The anterior uveitis is usually mild and responds to topical steroids. Additional immuno-suppression may not be needed. Mild ocular inflammation following vaccination should not deter individuals from getting COVID-19 vaccination | ||
| 650 | 4 | |a Case Reports | |
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Comment | |
| 650 | 4 | |a Adalimumab | |
| 650 | 4 | |a COVID-19 vaccination | |
| 650 | 4 | |a dengue hepatitis | |
| 650 | 4 | |a methotrexate | |
| 650 | 4 | |a recurrent anterior uveitis | |
| 650 | 7 | |a COVID-19 Vaccines |2 NLM | |
| 650 | 7 | |a HLA-B27 Antigen |2 NLM | |
| 700 | 1 | |a Kawali, Ankush |e verfasserin |4 aut | |
| 700 | 1 | |a Mahendradas, Padmamalini |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Indian journal of ophthalmology |d 1971 |g 71(2023), 5 vom: 01. Mai, Seite 2269-2272 |w (DE-627)NLM000735493 |x 1998-3689 |7 nnns |
| 773 | 1 | 8 | |g volume:71 |g year:2023 |g number:5 |g day:01 |g month:05 |g pages:2269-2272 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.4103/ijo.IJO_2064_22 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 71 |j 2023 |e 5 |b 01 |c 05 |h 2269-2272 | ||